Antibiotics developer MGB Biopharma's lead candidate exploits University of Strathclyde research, and it has just raised an undislcosed amount of new capital.

MGB Biopharma, a UK-based antibiotics developer based on University of Strathclyde’s research, raised an undisclosed amount on Friday in a round led by syndicate Archangel Investors. The oversubscribed round also featured Scottish Investment Bank (SIB), part of state economic development agency Scottish Enterprise, as well as venture capital firm Barwell and angel group TRI Capital.…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.